TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
邵幼雲SHAO, YU-YUN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
83筆
11
Li-Chun Lu, Chiun Hsu, Yu-Yun Shao, Yee Chao, Chia-Jui Yen, I-Lun Shih, Yi-Ping Hung, Chun-Jung Chang, Ying-Chun Shen, Jhe-Cyuan Guo, Tsung-Hao Liu, Chih-Hung Hsu, Ann-Lii Cheng. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer 2019 Nov; 8:480–490.#
12
Yu-Yun Shao, Tsung-Hao Liu, Chiun Hsu, Li-Chun Lu, Yin-Chung Shen, Zhong-Zhe Lin, Ann-Lii Cheng, Chih-Hung Hsu. Early Alpha-Fetoprotein Response Associated with Treatment Efficacy of Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Liver International 2019 Nov; 39: 2184-2189.#
13
Jhe-Cyuan Guo, Chia-Chi Lin, Chen-Yuan Lin, Min-Shu Hsieh, Hung-Yang Kuo, Ming-Yu Lien, Yu-Yun Shao, Ta-Chen Huang and Chih-Hung Hsu. Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research 2019 Oct; 39:5675-5682.#
14
Yu-Yun Shao, Yong-Shi Li, Hung-Wei Hsu, Hang Lin, Han-Yu Wang, Rita Wo, Ann-Lii Cheng, Chih-Hung Hsu. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers 2019 Sep; 11: 1433.#
15
Wen-Chi Chou, Jen-Shi Chen, Chia-Yen Hung, Chang-Hsien Lu, Yu-Yun Shao, Tzeon-Jye Chiou, Yung-Chuan Sung, Kun-Ming Rau, Chia-Jui Yen, Su-Peng Yeh, Ta-Chih Liu, Ming-Fang Wu, Ming-Yang Lee, Ming-Sun Yu, Wen-Li Hwang, Pang-Yu Lai, Cheng-Shyong Chang, Ruey-Kuen Hsieh. A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. Supportive Care in Cancer 2019 Aug; 27: 2857-2867#
16
Shih-Feng Cho, Kun-Ming Rau, Yu-Yun Shao, Chia-Jui Yen, Ming-Fang Wu, Jen-Shi Chen, Cheng-Shyong Chang, Su-Peng Yeh, Tzeon-Jye Chiou, Ruey-Kuen Hsieh, Ming-Yang Lee, Yung-Chuan Sung, Kuan-Der Lee, Pang-Yu Lai, Ming-Sun Yu, Wen-Li Hwang, Ta-Chih Liu. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. Supportive Care in Cancer 2019 May; 27: 1663–1672#
17
Tsung-Hao Liu, Yu-Yun Shao, Li-Chun Lu, Ying-Chun Shen, Chiun Hsu, Zhong-Zhe Lin, Chih-Hung Hsu & Ann-Lii Cheng. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019 May; 13: 615-621#
18
Tony O’Brien, Jin Seok Ahn, Richard Chye, Brian Le, Henry Lu, Gabriel Olarte, Mariana Palladini, Amar Salti, Yu-Yun Shao, Hayati Yaakup, Kristal Cielo Buemio, Consuelo Gutierrez Colin, Yacine Hadjiat. Understanding Transdermal Buprenorphine and a Practical Guide to its Use for Chronic Cancer and Non-Cancer Pain Management. Journal of Opioid Management 2019 Mar; 15: 147-158
19
Li-Chun Lu, Yi-Hsuan Lee, Chun-Jung Chang, Chia-Tung Shun, Chih-Yeu Fang, Yu-Yun Shao, Tsung-Hao Liu, Ann-Lii Cheng, Chih-Hung Hsu. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer 2019 Mar; 8:110–120#
20
Shih-Hung Yang, Yu-Yun Shao, Chia-Chi Lin, Sung-Hsin Kuo, Ann-Lii Cheng, Kun-Huei Yeh. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research 2018 Aug; 38: 4805-4812#
